1
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
2
Country: USA | Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
3
Country: Germany | Funding: $2.1B
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
4
Country: China | Funding: $1.4B
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
5
Country: USA | Funding: $510.6M
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
6
Country: USA | Funding: $360.1M
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.
7
Country: USA | Funding: $332M
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
8
Country: USA | Funding: $321M
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
9
Country: USA | Funding: $293.3M
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
10
Country: USA | Funding: $277.5M
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
11
Country: USA | Funding: $270M
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
12
Country: USA | Funding: $270M
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease.
13
Country: USA | Funding: $241M
Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary and biochip-based platform.
Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary and biochip-based platform.
14
Country: USA | Funding: $211M
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
15
Country: USA | Funding: $207M
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
16
Country: USA | Funding: $200M
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
17
Country: USA | Funding: $178M
Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
18
Country: USA | Funding: $159M
Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
19
Country: USA | Funding: $135M
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
20
Country: USA | Funding: $104.2M
Strand is creating mRNA “programming language,” creating the world’s first platform for mRNA smart therapies.
Strand is creating mRNA “programming language,” creating the world’s first platform for mRNA smart therapies.
